PHOTOCURE ASA (PHO.OL) Stock Fundamental Analysis
OSL:PHO - Euronext Oslo - NO0010000045 - Common Stock - Currency: NOK
We assign a fundamental rating of 5 out of 10 to PHO. PHO was compared to 52 industry peers in the Pharmaceuticals industry. PHO has a great financial health rating, but its profitability evaluates not so good. PHO is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year PHO was profitable.
PHO had a positive operating cash flow in the past year.
In the past 5 years PHO reported 4 times negative net income.
PHO had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 0.30%, PHO is doing worse than 65.38% of the companies in the same industry.
PHO has a worse Return On Equity (0.45%) than 65.38% of its industry peers.
Looking at the Return On Invested Capital, with a value of 1.79%, PHO is doing worse than 65.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.3% | ||
| ROE | 0.45% | ||
| ROIC | 1.79% |
ROA(3y)-3.44%
ROA(5y)-3.42%
ROE(3y)-5.33%
ROE(5y)-5.31%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of PHO (0.40%) is worse than 63.46% of its industry peers.
PHO has a Operating Margin of 2.64%. This is in the lower half of the industry: PHO underperforms 63.46% of its industry peers.
In the last couple of years the Operating Margin of PHO has declined.
Looking at the Gross Margin, with a value of 93.97%, PHO belongs to the top of the industry, outperforming 94.23% of the companies in the same industry.
In the last couple of years the Gross Margin of PHO has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.64% | ||
| PM (TTM) | 0.4% | ||
| GM | 93.97% |
OM growth 3YN/A
OM growth 5Y-23.87%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.29%
GM growth 5Y0.46%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PHO is destroying value.
Compared to 1 year ago, PHO has about the same amount of shares outstanding.
The number of shares outstanding for PHO has been increased compared to 5 years ago.
Compared to 1 year ago, PHO has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 5.39 indicates that PHO is not in any danger for bankruptcy at the moment.
PHO has a Altman-Z score of 5.39. This is amongst the best in the industry. PHO outperforms 82.69% of its industry peers.
There is no outstanding debt for PHO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 5.39 |
ROIC/WACC0.21
WACC8.52%
2.3 Liquidity
A Current Ratio of 3.81 indicates that PHO has no problem at all paying its short term obligations.
The Current ratio of PHO (3.81) is better than 94.23% of its industry peers.
PHO has a Quick Ratio of 3.44. This indicates that PHO is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of PHO (3.44) is better than 96.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.81 | ||
| Quick Ratio | 3.44 |
3. Growth
3.1 Past
PHO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -86.67%.
PHO shows a small growth in Revenue. In the last year, the Revenue has grown by 3.95%.
PHO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.29% yearly.
EPS 1Y (TTM)-86.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.97%
Revenue 1Y (TTM)3.95%
Revenue growth 3Y13.37%
Revenue growth 5Y13.29%
Sales Q2Q%6.19%
3.2 Future
PHO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 190.44% yearly.
Based on estimates for the next years, PHO will show a quite strong growth in Revenue. The Revenue will grow by 14.98% on average per year.
EPS Next Y896.78%
EPS Next 2Y264.59%
EPS Next 3Y190.44%
EPS Next 5YN/A
Revenue Next Year11.38%
Revenue Next 2Y11.91%
Revenue Next 3Y11.59%
Revenue Next 5Y14.98%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 3070.00 indicates a quite expensive valuation of PHO.
71.15% of the companies in the same industry are cheaper than PHO, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 27.53. PHO is valued rather expensively when compared to this.
A Price/Forward Earnings ratio of 30.21 indicates a quite expensive valuation of PHO.
Based on the Price/Forward Earnings ratio, PHO is valued a bit more expensive than the industry average as 67.31% of the companies are valued more cheaply.
When comparing the Price/Forward Earnings ratio of PHO to the average of the S&P500 Index (36.71), we can say PHO is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3070 | ||
| Fwd PE | 30.21 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PHO is valued a bit more expensive than 67.31% of the companies in the same industry.
PHO's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 25.75 | ||
| EV/EBITDA | 31.69 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PHO does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as PHO's earnings are expected to grow with 190.44% in the coming years.
PEG (NY)3.42
PEG (5Y)N/A
EPS Next 2Y264.59%
EPS Next 3Y190.44%
5. Dividend
5.1 Amount
No dividends for PHO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
OSL:PHO (7/23/2025, 3:50:39 PM)
61.4
+1.4 (+2.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners43.92%
Inst Owner ChangeN/A
Ins Owners1.95%
Ins Owner ChangeN/A
Market Cap1.67B
Analysts82.5
Price Target79.05 (28.75%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-94.41%
Min EPS beat(2)-203.96%
Max EPS beat(2)15.13%
EPS beat(4)2
Avg EPS beat(4)-37.97%
Min EPS beat(4)-203.96%
Max EPS beat(4)47.82%
EPS beat(8)5
Avg EPS beat(8)40.12%
EPS beat(12)6
Avg EPS beat(12)-9.06%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-3.7%
Min Revenue beat(2)-5.24%
Max Revenue beat(2)-2.17%
Revenue beat(4)1
Avg Revenue beat(4)-3.95%
Min Revenue beat(4)-9.78%
Max Revenue beat(4)1.4%
Revenue beat(8)3
Avg Revenue beat(8)-3.64%
Revenue beat(12)6
Avg Revenue beat(12)-2.7%
Revenue beat(16)7
Avg Revenue beat(16)-4.28%
PT rev (1m)0%
PT rev (3m)-7.74%
EPS NQ rev (1m)-150%
EPS NQ rev (3m)-150%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.75%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.83%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3070 | ||
| Fwd PE | 30.21 | ||
| P/S | 3.13 | ||
| P/FCF | 25.75 | ||
| P/OCF | 21.98 | ||
| P/B | 3.53 | ||
| P/tB | 7.05 | ||
| EV/EBITDA | 31.69 |
EPS(TTM)0.02
EY0.03%
EPS(NY)2.03
Fwd EY3.31%
FCF(TTM)2.38
FCFY3.88%
OCF(TTM)2.79
OCFY4.55%
SpS19.64
BVpS17.4
TBVpS8.71
PEG (NY)3.42
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.3% | ||
| ROE | 0.45% | ||
| ROCE | 2.32% | ||
| ROIC | 1.79% | ||
| ROICexc | 3.13% | ||
| ROICexgc | 9.81% | ||
| OM | 2.64% | ||
| PM (TTM) | 0.4% | ||
| GM | 93.97% | ||
| FCFM | 12.14% |
ROA(3y)-3.44%
ROA(5y)-3.42%
ROE(3y)-5.33%
ROE(5y)-5.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-14.8%
ROICexc growth 3YN/A
ROICexc growth 5Y-32.88%
OM growth 3YN/A
OM growth 5Y-23.87%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.29%
GM growth 5Y0.46%
F-Score5
Asset Turnover0.75
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 38.09% | ||
| Cap/Sales | 2.08% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 175.53% | ||
| Profit Quality | 3024.79% | ||
| Current Ratio | 3.81 | ||
| Quick Ratio | 3.44 | ||
| Altman-Z | 5.39 |
F-Score5
WACC8.52%
ROIC/WACC0.21
Cap/Depr(3y)33%
Cap/Depr(5y)196.94%
Cap/Sales(3y)1.85%
Cap/Sales(5y)14.41%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-86.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.97%
EPS Next Y896.78%
EPS Next 2Y264.59%
EPS Next 3Y190.44%
EPS Next 5YN/A
Revenue 1Y (TTM)3.95%
Revenue growth 3Y13.37%
Revenue growth 5Y13.29%
Sales Q2Q%6.19%
Revenue Next Year11.38%
Revenue Next 2Y11.91%
Revenue Next 3Y11.59%
Revenue Next 5Y14.98%
EBIT growth 1Y-61.13%
EBIT growth 3YN/A
EBIT growth 5Y-13.75%
EBIT Next Year105.28%
EBIT Next 3Y59.66%
EBIT Next 5YN/A
FCF growth 1Y1030.99%
FCF growth 3Y47.91%
FCF growth 5Y27.04%
OCF growth 1Y590.65%
OCF growth 3Y47.56%
OCF growth 5Y30.02%